News of Note—GeoVax, mumps outbreak and more
admin 7th November 2017 Uncategorised 0Here is some other vaccine news of note for this week. More: News of Note—GeoVax, mumps outbreak and more Source: fierce
read more
Here is some other vaccine news of note for this week. More: News of Note—GeoVax, mumps outbreak and more Source: fierce
read moreVaccine producers have made flu shots with eggs for decades, but egg-based production interfered with the efficacy of last year’s vaccine, a new study says. What’s worse, the problem could repeat this season. More: Industry's favored flu shot production process
read moreOn last week’s third-quarter earnings call, interim Teva CFO Mike McClellan told investors that executives would be “evaluating all options” for easing the company’s debt burden. But that list of options is shrinking. More: Teva's debt-easing options narrow as Fitch
read moreValeant’s third-quarter results provided a welcome dose of good news as the company works to execute its lengthy turnaround. Point one: It’s paid off $6 billion of its monstrous debt load. But point two? Sales were down 10%, despite growth
read moreTakeda’s experimental dengue vaccine just became a clearer threat to Sanofi’s Dengvaxia as the latest 18-month interim phase 2 data showed Takeda’s shot induced sustained antibody responses, regardless of previous dengue exposure. More: With interim phase 2 data, Takeda’s dengue
read moreBayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease. More: Bayer files low-dose Xarelto/aspirin combo Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals